Important Information Regarding Supply of Hydroxyurea
Published on: November 09, 2011
ASH has heard from members who have experienced difficulty in obtaining Hydroxyurea (generic names: Droxia and Hydrea), a drug that is used for various conditions including chronic myelocytic leukemia and sickle cell anemia. Members report that this is mainly a problem for their patients who are unable to obtain immediate refills of their Hydroxyurea prescription at their local pharmacies. ASH alerted the U.S. Food & Drug Administration (FDA) about the Society's concerns and contacted the three manufacturers of Hydroxyurea: Teva Pharmaceutical, Bristol-Myers Squibb, and Par Pharmaceutical. Teva reports that it is experiencing a shortage of the therapy and it expects a release date of at least late January to early February. Bristol-Myers Squibb, and Par report they have adequate supplies of the therapy and do not anticipate any complications.
ASH would like your help in tracking shortage problems of this product. If you are experiencing any problems accessing Hydroxyurea, please contact ASH Government Relations Manager Stephanie Kaplan at email@example.com or 202-776-0544. In addition, if you need product, you may contact Par Customer Service at 201-802-4000.